AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis

Clinical trial NCT07619638 · RECRUITING

Trial details

NCT number: NCT07619638
Sponsor: ENBIOSIS BIOTECHNOLOGIES
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Colitis

Start date: 2026-06-10
Primary completion: 2027-05-30
Enrollment: 162

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.